AOP-Wiki

API

All Key Events

Showing 976 to 1000 of 1939 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

1415	Reduced, GABA-A receptor activation Short Name Reduced, GABA-A receptor activation	0	Molecular	Jun 2, 2017	Jun 2, 2017	231: presynaptic neuron 2 repression to epilepsy
1414	Decreased, GABA Short Name Decreased, GABA	0	Cellular	Jun 2, 2017	Jun 2, 2017	231: presynaptic neuron 2 repression to epilepsy
1413	Reduced, presynaptic neuron 2 activity Short Name Reduced, presynaptic neuron 2 activity	0	Cellular	Jun 2, 2017	Jun 2, 2017	231: presynaptic neuron 2 repression to epilepsy
1412	Helicobacter pylori infection Short Name Helicobacter pylori infection	0	Tissue	Jun 2, 2017	Jun 2, 2017	229: Helicobacter pylori to gastric ulcer
1411	Increased, leukocyte activation Short Name Increased, leukocyte activation	0	Tissue	Jun 2, 2017	Jun 2, 2017	228: NSAID induced PTGS2 inactivation to gastric ulcer
1410	Increased, leukocyte adherence Short Name Increased, leukocyte adherence	0	Tissue	Jun 2, 2017	Jun 2, 2017	228: NSAID induced PTGS2 inactivation to gastric ulcer
1409	Decreased, angiogenesis Short Name Decreased, angiogenesis	0	Tissue	Jun 2, 2017	Jun 2, 2017	228: NSAID induced PTGS2 inactivation to gastric ulcer
1408	Reduced, PTGS2 function Short Name Reduced, PTGS2 function	0	Cellular	Jun 2, 2017	Jun 2, 2017	228: NSAID induced PTGS2 inactivation to gastric ulcer
1407	Decreased, bicarbonate Short Name Decreased, bicarbonate	0	Tissue	Jun 2, 2017	Jun 2, 2017	227: NSAID induced PTGS1 inactivation to gastric ulcer
1406	Decreased, mucous Short Name Decreased, mucous	0	Tissue	Jun 2, 2017	Jun 2, 2017	227: NSAID induced PTGS1 inactivation to gastric ulcer
1405	Reduced, mucosal defense Short Name Reduced, mucosal defense	0	Tissue	Jun 2, 2017	Jun 2, 2017	2 AOPs 227: NSAID induced PTGS1 inactivation to gastric ulcer 229: Helicobacter pylori to gastric ulcer
1404	Decreased, mucosal blood flow Short Name Decreased, mucosal blood flow	0	Tissue	Jun 2, 2017	Jun 2, 2017	227: NSAID induced PTGS1 inactivation to gastric ulcer
1403	Reduced, platelet aggregation Short Name Reduced, platelet aggregation	0	Tissue	Jun 2, 2017	Jun 2, 2017	227: NSAID induced PTGS1 inactivation to gastric ulcer
1402	Reduced, PTGS1 function Short Name Reduced, PTGS1 function	0	Molecular	Jun 2, 2017	Jun 2, 2017	227: NSAID induced PTGS1 inactivation to gastric ulcer
1401	Decreased, 5-HT3 Short Name Decreased, 5-HT3	0	Tissue	Jun 1, 2017	Jun 1, 2017	223: Serotonin transporter activation to seizure
1400	Increased, synaptic release Short Name Increased, synaptic release	0	Cellular	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1399	Increased, packaged serotonin Short Name Increased, packaged serotonin	0	Cellular	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1398	Increased, intracellular serotonin Short Name Increased, intracellular serotonin	0	Cellular	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1397	Increased, serotonin transporter activity Short Name	0	Cellular	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1396	Increased, glucocorticoid receptor activity Short Name	0	Molecular	May 31, 2017	May 31, 2017	2 AOPs 221: Mental stress to depression 222: Mental stress to agitation
1395	Liver Cancer Short Name Liver Cancer	0	Organ	May 30, 2017	Jun 19, 2021	2 AOPs 220: Cyp2E1 Activation Leading to Liver Cancer 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
1394	Induction, persistent proliferation/sustained proliferation Short Name Sustained proliferation	4	Cellular	May 30, 2017	Jun 19, 2021	220: Cyp2E1 Activation Leading to Liver Cancer
1393	Hepatocytotoxicity Short Name Hepatocytotoxicity	0	Cellular	May 30, 2017	Jun 19, 2021	220: Cyp2E1 Activation Leading to Liver Cancer
1392	Increase, Oxidative Stress Short Name Increase, Oxidative Stress	1	Molecular	May 30, 2017	Feb 11, 2026	70 AOPs 220: Cyp2E1 Activation Leading to Liver Cancer 17: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory 284: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress leads to chronic kidney disease 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 411: Oxidative stress Leading to Decreased Lung Function 424: Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction 425: Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 429: A cholesterol/glucose dysmetabolism initiated Tau-driven AOP toward memory loss (AO) in sporadic Alzheimer's Disease with plausible MIE's plug-ins for environmental neurotoxicants 452: Adverse outcome pathway of PM-induced respiratory toxicity 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits 470: Deposition of energy leads to abnormal vascular remodeling 478: Deposition of energy leading to occurrence of cataracts 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases. 482: Deposition of energy leading to occurrence of bone loss 483: Deposition of Energy Leading to Learning and Memory Impairment 505: Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway 521: Essential element imbalance leads to reproductive failure via oxidative stress 26: Calcium-mediated neuronal ROS production and energy imbalance 488: Increased reactive oxygen species production leading to decreased cognitive function 396: Deposition of ionizing energy leads to population decline via impaired meiosis 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity 535: Binding and activation of GPER leading to learning and memory impairments 171: Chronic cytotoxicity of the serous membrane leading to pleural/peritoneal mesotheliomas in the rat. 138: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality 177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality 186: unknown MIE leading to renal failure and mortality 200: Estrogen receptor activation leading to breast cancer 444: Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways 260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration 450: Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality 501: Excessive iron accumulation leading to neurological disorders 540: Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production 471: Neuron defect induced early behavioral change 31: Oxidation of iron in hemoglobin leading to hematotoxicity 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 462: Activation of reactive oxygen species leading the atherosclerosis 331: Reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 595: Emerging OPFRS reproductive outcome pathway 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 608: Thyroid Hormone Excess Leading to Reduced, Swimming Performance via Hypomyelination 616: organic UV filter and its Photoproducts reproductive toxicity pathways 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 472: DNA adduct formation leading to kidney failure 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation 324: Reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 326: Reactive oxygen species leading to growth inhibition via lipid peroxidation and decreased cell proliferation 332: Reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation 333: Reactive oxygen species leading to growth inhibition via protein oxidation and cell death 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
1391	Activation of Cyp2E1 Short Name Activation of Cyp2E1	0	Molecular	May 30, 2017	Jun 19, 2021	2 AOPs 220: Cyp2E1 Activation Leading to Liver Cancer 450: Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality